|
|
3.1 Tabac
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
|
5. Traitements
|
|
|
A better way to treat cancer: understanding tumors [Fortune]
|
|
|
|
|
|
Ultimately
precision medicine will only be as precise as available data allows. To
better understand complex diseases like cancer, the medical and tech
industries must collaborate to make the growing wealth of public and
private genetic data sets accessible for patient benefit.
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
|
Verastem Takes a Tumble [In the Pipeline]
|
|
|
|
|
|
They
went into the clinic with a possible mesothelioma therapy, the FAK
inhibitor VS-6063 (defactinib), although you had to wonder how much that
one had to do with the company’s putative stem-cell mission.
|
|
|
|
|
|
|
|
Cometriq plays wallflower as Opdivo’s dance card fills [EP Vantage]
|
|
|
|
|
|
Cometriq
will not be able to escape comparisons with Opdivo. The first blow was
their near-simultaneous release of positive results in renal cell
carcinoma in July, and on Saturday they were put side by side in a
late-breaking data session at the European Cancer Congress in Vienna.
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
5.6.10 ESMO - Vessie
|
|
|
Bladder Cancer Treatment IMvigor-ated [The OBR Blog]
|
|
|
|
|
|
In
the U.S., accelerated approval of atezolizumab in this indication is
highly likely given the lack of any approved therapies for relapsed
patients and with the drug having already received Breakthrough Therapy
designation in this indication.
|
|
|
|
|
|
|
|
5.6.11 ESMO- Rein
|
|
|
|
|
In A First, Kidney Cancer Drug Extends Survival [Forbes]
|
|
|
|
|
|
The
NEJM has published two papers on kidney cancer treatment to coincide
with their presentation at theEuropean Cancer Congress in Vienna. While
neither study yields fantastic results, each demonstrates a significant
benefit for a new drug in patients with advanced, refractory renal cell
(kidney) tumors.
|
|
|
|
|
|
|
5.6.12 ESMO - Observation
|
|
|
|
|
|
5.6.13 ESMO - Prostate
|
|
|
|
|
5.6.2 ESMO - Divers
|
|
|
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
|
|
|
5.6.5 ESMO - Mélanome & Peau
|
|
|
|
5.6.6 ESMO - Sein
|
|
|
|
|
|
5.6.8 ESMO - Côlon-rectum
|
|
|
|
|
6.4 Médico-éco
|
|
|
Patients Are Seen as Potential Donors, Many Doctors Say [NY Times]
|
|
|
|
|
|
A
well-to-do cancer patient is nearing the end of her treatments. During
an office visit, she says to her doctor, “I can’t thank you enough for
the care you provided.” Should the doctor simply accept the patient’s
gratitude — or gently suggest a way for her to show it: “Perhaps you
might consider making a donation?”
|
|
|
|
|
6.8 Communication
|
|
|
May I take your metaphor? – how we talk about cancer [Cancer Research UK]
|
|
|
|
|
|
Whether
you’re a patient, a carer, a fundraiser or a doctor – talking about
cancer almost invariably means using metaphors. But is one metaphor
better than another? And how do different metaphors affect different
people? That’s the question Professor Elena Semino, a linguist from
Lancaster University, has spent the last few years trying to figure out.
|
|
|
|